Abstract

ObjectivesTo evaluate the use of continuous interscalene brachial plexus block with bupivacaine to treat complex regional pain syndrome (CRPS) type 1 of the shoulder in adult patients who were refractory to standard therapies. Patients and methodsWe performed a prospective, cross-sectional study of 59 cases of treatment-refractory CRPS type 1 of the shoulder. The patients were treated with one week of continuous interscalene brachial plexus block with bupivacaine and concomitant rehabilitation in a specialist centre. After withdrawal of the catheter, rehabilitation was continued for a further 3 weeks.The outcomes at 1, 6 and 12 months were evaluated in terms of the Constant score, the verbal numeric rating scale (VNRS) for pain, joint range of motion and medication use. Patients were later interviewed by telephone and asked to state their professional situation, the current VNRS score for pain and the status of their CRPS. ResultsIn the first month of treatment, the mean VNRS pain score fell from 7.4 to 3.6, the Constant score rose from 21.7 to 56.6% and the joint range of motion increased from 5.4 to 29.9° for external rotation (ER) position 1 and from 38.6 to 74.2° for abduction. These improvements persisted over time, despite a very slight reduction at 6 months. 86% of the interviewed patients reported that the treatment protocol had improved or greatly improvement their condition. 46% of the respondees had been able to return to work. ConclusionTreatment with a combination of a 1-week continuous interscalene brachial plexus block and rehabilitation may be a good option for patients with CRPS type 1 of the shoulder and who are refractory to standard therapies.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.